In adults, recent evidence demonstrates that sleep and circadian physiology change across lunar phases, including findings that endogenous melatonin levels are lower near the full moon compared to the new moon. Here, we extend these results to early childhood by examining circalunar fluctuations in children's evening melatonin levels. We analysed extant data on young children's circadian rhythms (n = 46, aged 3.0-5.9 years, 59% female). After following a strict sleep schedule for 5-7 days, children completed an in-home, dim-light circadian assessment (<10 lux). Salivary melatonin was assessed at regular 20- to 30-min intervals until 1 h past each child's scheduled bedtime. Melatonin levels varied significantly across lunar phases, such that melatonin was lower in participants assessed near the full moon as compared to near the new moon. Significant differences were observed at 50 min (mean = 2.5 pg/ml; mean = 5.4 pg/ml) and 10 min (mean = 7.3 pg/ml; mean = 15.8 pg/ml) before children's scheduled bedtime, as well as at 20 min (mean = 15.5 pg/ml; mean = 26.1 pg/ml) and 50 min (mean = 19.9 pg/ml; mean = 34.3 pg/ml) after bedtime. To our knowledge, these are the first data demonstrating that melatonin secretion, a process regulated by the human circadian system, is sensitive to changes in lunar phase at an early age. Future research is needed to understand the mechanisms underlying this association (e.g., an endogenous circalunar rhythm) and its potential influence on children's sleep and circadian health.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659667 | PMC |
http://dx.doi.org/10.1111/jsr.13635 | DOI Listing |
Alzheimers Dement
December 2024
IGC Pharma, Potomac, MD, USA
Background: This study investigates the impact of IGC‐AD1, a combination comprising of low concentration of delta‐9 tetrahydrocannabinol (“THC”) and melatonin on blood serum potassium levels in patients with Alzheimer’s disease (“AD”). Loss of intracellular compartmentalization of potassium is a characteristic of AD pathology, with supporting studies indicating significantly lower potassium levels in intracellular compartments of AD brains and an associated increase in serum potassium levels in AD subjects. Here, we present preliminary safety lab data from a Phase I trial of AD patients administered with IGC‐AD1.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
IGC Pharma, Potomac, MD, USA
Background: IGC‐AD1 comprises of Tetrahydrocannabinol (“THC”) and melatonin. The two active pharmaceuticals are known for their neuroprotective properties. In this analysis we studied multiple dosing of IGC‐AD1 in Alzheimer’s (“AD”) populations vulnerable to hepatic complications.
View Article and Find Full Text PDFInt Urol Nephrol
January 2025
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
Objective: The objective of this systematic review and meta-analysis was to assess the efficacy of melatonin in drug- or contrast-induced AKI in preclinical and clinical studies.
Methods: PubMed, Embase, Scopus, Web of Science (WOS), the Cochrane Database of Systematic Reviews (CDSR), and clinical trials.GOV from the beginning until August 1, 2024.
Alzheimers Dement
December 2024
UK Dementia Research Institute, Care Research and Technology Centre, Imperial College London and the University of Surrey, Guildford, UK
Background: Disruption in diurnal rest‐activity rhythms is a hallmark of Alzheimer’s disease. Currently, we know little about how physiology, symptoms, and biomarkers change over the 24‐hour day in people living with Alzheimer’s disease. In particular, we don’t know whether plasma biomarkers of neurodegeneration, which offer promise as diagnostic or stratification tools, vary with time of day, and whether these associate with the circadian markers melatonin and cortisol.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Yuan Ze University, Taoyuan CIty, Taoyuan, Taiwan
Background: Effect of dynamic lighting on sleep were studied since 1980’s. Traditional light sources were used due to lack of advancement in technology and also researchers assumed illuminance as cause of melatonin suppression. This led researchers to use high illuminance to suppress melatonin at day time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!